Cargando…
Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014
BACKGROUND: Kaposi's sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of Kaposi's sarcoma in Zambia...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Medical Association Of Malawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788595/ https://www.ncbi.nlm.nih.gov/pubmed/35140843 http://dx.doi.org/10.4314/mmj.v32i2.4 |
_version_ | 1784639602204606464 |
---|---|
author | Kalubula, Maybin Shen, Heqing Makasa, Mpundu |
author_facet | Kalubula, Maybin Shen, Heqing Makasa, Mpundu |
author_sort | Kalubula, Maybin |
collection | PubMed |
description | BACKGROUND: Kaposi's sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of Kaposi's sarcoma in Zambia from 2007 – 2014. METHODS: We conducted the descriptive epidemiology of Kaposi's sarcoma in Zambia nested on two data sources; the Zambia National Cancer Registry (ZNCR) Kaposi's sarcoma (KS) data, and population-based HIV data from the Zambia National AIDS Council (NAC). Central Statistics Office (CSO) demographic data were used to determine the prevalence and annual incidence of KS. KS sample was 2521while HIV data from NAC were already population-based (HIV impact assessment survey). We used Microsoft Excel and SPSS version 21 in graphical computation and statistical analyses. RESULTS: Both HIV and KS were highly prevalent in Lusaka, Central, and Southern provinces. ART coverage ranged from 40% – 60%; HIV prevalence was 14.9% in females and 9.5% in males while KS prevalence was 13/100,000 in females and 21/100,000 in males. HIV prevalence was associated with KS prevalence with r = 0.827 and a p-value of 0.001 in males, and r = 0.898 with a p-value of 0.000 in females. There were 61% confirmed HIV seropositive KS, 18% confirmed HIV seronegative KS and 21% unknown HIV status KS. CONCLUSION: The high prevalence of KS in Zambia is as a result of the high prevalence of HIV. The identified two key interventions for the reduction of KS morbidity are; reducing HIV infection rate and improving ART coverage across the country. |
format | Online Article Text |
id | pubmed-8788595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Medical Association Of Malawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-87885952022-02-08 Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 Kalubula, Maybin Shen, Heqing Makasa, Mpundu Malawi Med J Original Research BACKGROUND: Kaposi's sarcoma (KS) is the most prevalent HIV and AIDS-associated cancer in the world. Zambia has been considered as part of the “KS belt”, where endemic KS has been prevalent. This study, therefore, aimed to present the descriptive epidemiology of Kaposi's sarcoma in Zambia from 2007 – 2014. METHODS: We conducted the descriptive epidemiology of Kaposi's sarcoma in Zambia nested on two data sources; the Zambia National Cancer Registry (ZNCR) Kaposi's sarcoma (KS) data, and population-based HIV data from the Zambia National AIDS Council (NAC). Central Statistics Office (CSO) demographic data were used to determine the prevalence and annual incidence of KS. KS sample was 2521while HIV data from NAC were already population-based (HIV impact assessment survey). We used Microsoft Excel and SPSS version 21 in graphical computation and statistical analyses. RESULTS: Both HIV and KS were highly prevalent in Lusaka, Central, and Southern provinces. ART coverage ranged from 40% – 60%; HIV prevalence was 14.9% in females and 9.5% in males while KS prevalence was 13/100,000 in females and 21/100,000 in males. HIV prevalence was associated with KS prevalence with r = 0.827 and a p-value of 0.001 in males, and r = 0.898 with a p-value of 0.000 in females. There were 61% confirmed HIV seropositive KS, 18% confirmed HIV seronegative KS and 21% unknown HIV status KS. CONCLUSION: The high prevalence of KS in Zambia is as a result of the high prevalence of HIV. The identified two key interventions for the reduction of KS morbidity are; reducing HIV infection rate and improving ART coverage across the country. The Medical Association Of Malawi 2020-06 /pmc/articles/PMC8788595/ /pubmed/35140843 http://dx.doi.org/10.4314/mmj.v32i2.4 Text en © 2020 The College of Medicine and the Medical Association of Malawi. https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Original Research Kalubula, Maybin Shen, Heqing Makasa, Mpundu Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 |
title | Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 |
title_full | Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 |
title_fullStr | Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 |
title_full_unstemmed | Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 |
title_short | Epidemiology of Kaposi's sarcoma in Zambia, 2007 – 2014 |
title_sort | epidemiology of kaposi's sarcoma in zambia, 2007 – 2014 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788595/ https://www.ncbi.nlm.nih.gov/pubmed/35140843 http://dx.doi.org/10.4314/mmj.v32i2.4 |
work_keys_str_mv | AT kalubulamaybin epidemiologyofkaposissarcomainzambia20072014 AT shenheqing epidemiologyofkaposissarcomainzambia20072014 AT makasampundu epidemiologyofkaposissarcomainzambia20072014 |